Astellas Pharma (OTCMKTS:ALPMY) Sees Strong Trading Volume – Here’s Why

Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY) saw unusually-strong trading volume on Tuesday . Approximately 112,791 shares were traded during trading, a decline of 33% from the previous session’s volume of 168,276 shares.The stock last traded at $13.58 and had previously closed at $13.25.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 23rd. Two investment analysts have rated the stock with a Strong Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy”.

Astellas Pharma Trading Down 2.2%

The stock’s 50 day moving average is $13.55 and its two-hundred day moving average is $14.65. The company has a market capitalization of $24.06 billion, a PE ratio of 12.38 and a beta of 0.07. The company has a quick ratio of 0.90, a current ratio of 1.17 and a debt-to-equity ratio of 0.17.

Astellas Pharma (OTCMKTS:ALPMY) last posted its earnings results on Monday, April 27th. The company reported $0.33 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.14. Astellas Pharma had a net margin of 13.66% and a return on equity of 23.54%. The business had revenue of $3.38 billion for the quarter, compared to the consensus estimate of $3.28 billion. As a group, sell-side analysts predict that Astellas Pharma Inc. will post 1.25 EPS for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).